Immatics Announces $35 Million Equity Investment from Bristol Myers Squibb Tuebingen, Germany and Houston, TX

Announces $35 Million Equity Investment from Bristol Myers Squibb

and Houston, TX July 24, 2023 - Immatics N.V.

(NASDAQ: IMTX, "Immatics"), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting

cancer immunotherapies, today announced that Bristol Myers Squibb (NYSE: BMY) has made a $35 million equity investment in Immatics. Bristol

Myers Squibb purchased 2,419,818 ordinary shares in a private placement transaction at a subscription price per share of $14.461.

Additionally, Bristol Myers Squibb has the right to appoint a member to the Immatics Scientific Advisory Board.

is further testimony to the strength of the relationship and of our differentiated platform technologies that are the foundation of our

TCR-based cell therapies and bispecifics," commented Harpreet Singh, Ph.D., CEO and Co-Founder of Immatics. "We remain steadfast

in our commitment to advancing innovative treatment options for patients in their fight against cancer, and look forward to providing

further clinical results in the second half of the year."

The securities referenced

above have not been registered under the Securities Act of 1933, as amended, or any state or other applicable jurisdiction's securities

laws, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements

of the Securities Act and applicable state or other jurisdictions' securities laws.

the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling

a robust and specific T cell response against these targets. This deep know-how is the foundation for our pipeline of Adoptive Cell Therapies

and TCR Bispecifics as well as our partnerships with global leaders in the pharmaceutical industry. We are committed to delivering the

power of T cells and to unlocking new avenues for patients in their fight against cancer.

Twitter and LinkedIn.

price per share $14.4639

in this press release may be considered forward-looking statements. Forward-looking statements generally relate to future events or Immatics'

future financial or operating performance. For example, statements concerning the timing of product candidates and Immatics' focus

on partnerships to advance its strategy are forward-looking statements. In some cases, you can identify forward-looking statements by

terminology such as "may", "should", "expect", "intend", "will", "estimate",

"anticipate", "believe", "predict", "potential" or "continue", or the negatives

of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and

other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements.

These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Immatics and its management,

are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties.

Factors that may cause actual results to differ materially from current expectations include, but are not limited to, various factors

beyond management's control including general economic conditions and other risks, uncertainties and factors set forth in filings with

the SEC. Nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth

herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place

undue reliance on forward-looking statements, which speak only as of the date they are made. Immatics undertakes no duty to update these

forward-looking statements.

For more information,